Put companies on watchlist
HBM Healthcare Investments AG
ISIN: CH0012627250
WKN: 984345
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

HBM Healthcare Investments AG · ISIN: CH0012627250 · EQS - adhoc news (193 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 2061425
03 January 2025 05:48PM

HBM Healthcare Investments reports a compelling 15 percent increase in NAV in the 2024 calendar year


HBM Healthcare Investments AG / Key word(s): Quarter Results
HBM Healthcare Investments reports a compelling 15 percent increase in NAV in the 2024 calendar year

03-Jan-2025 / 17:48 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


HBM Healthcare Investments closed the calendar year 2024 with a strong performance. Its net asset value (NAV) per share rose by 15 percent to CHF 251.17. By contrast, the share price failed to reflect this good performance, growing only marginally by 0.5 percent to CHF 176.00. The market capitalisation is thus almost 30 percent or more than CHF 500 million below the NAV, which corresponds to practically the entire book value of the portfolio of private companies and thus takes into account neither its value nor its potential for added value.

In addition to listed companies, private companies made a significant contribution to performance (Johnson & Johnson's acquisition of Yellow Jersey Therapeutics and the IPO of Sai Life Sciences in India). In addition, most investment currencies appreciated against the Swiss franc, contributing 6.8%.

The relevant healthcare sector market indices, measured in Swiss francs, also performed positively, but all lagged behind HBM Healthcare Investments (MSCI World Health Care Index +9.9%, Nasdaq Biotechnology Index (NBI) +7.6% and SPDR S&P Biotech (XBI) +9.3%).

Positive results also in the first nine months of the 2024/2025 financial year

The NAV rose by 4.3 percent in the first nine months of the 2024/2025 financial year, resulting in a net profit of around CHF 66 million (previous year: net loss of CHF 157.5 million).

Performance during the period was mainly driven by the aforementioned private companies, while the listed companies were slightly negative. Foreign currencies had no significant impact.

The figures presented here are provisional based on the current status of the work on the financial statements. The final result will be published in the quarterly report on 20 January 2025.

Contact
For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com.



End of Inside Information
Language: English
Company: HBM Healthcare Investments AG
Bundesplatz 1
6300 Zug
Switzerland
Phone: +41438887171
Fax: +41438887172
E-mail: info@hbmhealthcare.com
Internet: https://www.hbmhealthcare.com
ISIN: CH0012627250
Valor: 1262725
Listed: SIX Swiss Exchange
EQS News ID: 2061425

 
End of Announcement EQS News Service

2061425  03-Jan-2025 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2061425&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - HBM Healthcare Investments AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.